NATCOPHARM / NSE / Biotechnology & Drugs
Natco Pharma
1Y Price Trend
Key Information
Recommendations
RatingHold
Target High1,226.1
Target Low789.3
Target Mean2.89
Target Median36.11
Risk Metrics
Overall RiskBalanced risk
Board Risk44.41
Key Analysis
Overall score, performance score, return rating, defensive, aggressive, and balanced views.
Download appProjection Analytics
Best-case, base-case, worst-case, and dynamic AI projection views.
Download appLatest stock news
Kaynes Technology and 3 Other Stocks Falling Due to Weak Q4 Results Trade Brains
Natco Pharma shares sink up to 15% after weak Q4 earnings MSN
Natco Pharma shares slump 15% after Q4 results; here's why the stock is falling MSN
Natco Pharma FY26 profit falls 25%; Q4 EBITDA margin at 25.1% scanx.trade
Lupin and Natco Secure US FDA Approval for Generic Eribulin Mesylate Injection Machine Maker
Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection IndiaMedToday
Pharma sector stocks today, June 4: Panacea Biotech up 7.24%, Wockhardt gains 3.09%, Natco Pharma falls 1.63% Business Upturn
Natco Pharma Ltd. Technical Momentum Shifts Amid Volatile Market Conditions Markets Mojo
© SharekeyX | Rusaka Technologies 2024-2026